Antimalarial therapy selection for quinolone resistance among Escherichia coli in the absence of quinolone exposure, in Tropical South America

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Davidson, Ross J ^a   Davis, Ian ^b,c   Willey, Barbara M ^d   Rizg, Keyro ^a   Bolotin, Shelly ^c   Porter, Vanessa ^d   Polsky, Jane ^e   Daneman, Nick ^c   McGeer, Allison ^c,d   Yang, Paul ^f   Scolnik, Dennis ^c   Rowsell, Roy ^b   Imas, Olga ^d   Silverman, Michael S ^b,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b LAKERIDGE HEALTH CORPORATION   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f ONTARIO MINISTRY OF THE ENVIRONMENT   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DRINKING WATER; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG CHOICE; DRUG EXPOSURE; EPIDEMIC; ESCHERICHIA COLI; FEMALE; GENE MUTATION; GRAM NEGATIVE BACTERIUM; GROWTH INHIBITION; HEALTH SURVEY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALARIA; MALE; NONHUMAN; PLASMODIUM VIVAX; PLATING MEDIUM; POLYMERASE CHAIN REACTION; PREVALENCE; PUBLIC HEALTH; RURAL AREA; SOUTH AMERICA; TROPICS; WATER ANALYSIS; ANIMAL; CHILD; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; MUTATION;

BACILLI (CLASS); BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA; PLASMODIUM VIVAX;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIMALARIALS; CHILD; DRUG RESISTANCE; ESCHERICHIA COLI; FEMALE; HUMANS; MALARIA, VIVAX; MALE; MIDDLE AGED; MUTATION; PLASMODIUM VIVAX; QUINOLONES; SOUTH AMERICA;

EID: 50249175996     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002727     Document Type: Article

References (36)

1. Goosens H, Ferech M, Stichele RF, Elseviers M, for the ESAC Project Group (2005) Outpatient antibiotic use in Europe and association with resistance: a cross national database study. Lancet 365: 579-87.
2. Turnidge J, Christiansen K (2005) Antibiotic use and resistance - Proving the obvious. Lancet 365: 547-8.
3. Nys S, Okeke IN, Kariuki S, Dinant GJ, Driessen C, et al. (2004) Antibiotic resistance of faecal Escherichia coli from healthy volunteers from eight developing countries. J Antimicrob Chemother 54: 952-5.
4. Okeke IN, Lamikanra A, Edleman R (1999) Socioeconomic and behavioural factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerging Infectious Diseases 5: 18-27.
5. Hart CA, Kariuki S (1998) Antimicrobial resistance in developing countries. BMJ 317: 647-50.
6. Hakanen A, Kotilainen P, Huovinen P, et al. (2001) Reduced fluoroquinolone susceptibility in Salmonella enteritica serotypes in travelers returning from Southeast Asia. Emerg Infect Dis 7: 996-1003.
7. Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, et al. (2007) Sulfadoxine-Pyrimethamine, Chlorproguanil-Dapsone, or Chloroquine for the Treatment of Plasmodium vivax Malaria in Afghanistan and Pakistan. JAMA 297: 2201-2209.
8. Guidelines for the Treatment of Malaria in the United States Center for Disease Control and Prevention. Department of Health and Human Services. Atlanta, GA. (Available at http://www.cdc.gov/malaria/pdf/ treatmenttable.pdf). Accessed Sept 22, 2007.
9. Arrow KJ, Gellband H, Jamieson DT (2005) Making Antimalarial Agents available in Africa. N Engl J Med 353: 333-335.
10. World Health Organization (2003) The Africa Malaria Report.
11. Lard LR, Visser H, Speyer I, vander Horst-Brunisma IE, Zwinderman AH, et al. (2001) Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: a comparison of two cohorts who received different treatment strategies. Am J Med 111: 446-51.
12. Ruiz-Irastorza G, Khamashta MA, Hughes GR (2000) Therapy of systemic lupus erythematosis: new agents and new evidence. Expert Opin Investig Drugs 9: 1581-93.
13. Cohen SN, Yielding KL (1965) Inhibition of DNA and RNA polymerase reactions by chloroquine. Proc Natl Acad Sci USA 54: 521-7.
14. Byrd TF, Horwitz MA (1991) Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest 88: 351-7.
15. Jain SK, Singh V, Gupta S (2003) In vitro susceptibility of chloroquine (4-aminoquinolones) against pathogenic bacteria. Ind J Microbiol 43: 147-8.
16. Ciarrocchi G, MacPhee DG, Deady LW, Tilley L (1999) Specific Inhibition of the Eubacterial DNA Ligase by Arylamino Compounds. Antimicrob Agents and Chemother 43: 2766-72.
17. Smith KT, Dawes W (1989) The preferential inhibition of Bacillus subtilis spore outgrowth by chloroquine. Arch Microbiol 152: 251-7.
18. Applebaum PC, Hunter PA (2000) The fluoroquinolone antibacterials: past, present and future perspectives. International J of Antimicrob Agents 16: 5-15.
19. Lesher GY, Froelich ED, Gruet MD, Bailey JH, Brundage RP (1962) 1-8 naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharmaceut Chem 5: 1063-8.
20. British Guyana. Amerindian District Order No.91 of 1959.
21. Anselmo LStatement of Paruima Village Captain made at the Regional Captains Conference, Kamarang. 26/06/1988.
22. Declaration from the Second Conference of Amerindian Peoples of Guyana (1991) April 11-14.
23. James T (2003) Indigenous Land Rights in Guyana; Past, Present and Future. Indigenous Rights of the Commonwealth Caribbean and Americas Regional Expert Meeting. Georgetown, Guyana June 23-5.
24. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, et al. (2003) Antibiotic Resistance among Gram-Negative Bacilli in US Intensive Care Units: Implications for Fluoroquinolone Use. JAMA 289: 885-8.
25. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman N (2005) Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Inf Dis 41: 923-9.
26. Willems TEChloroquine-resistant malaria: genetic origins and prospects for control. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL. Sep 19, 2007. L1290a.
27. Weigel LM, Steward CD, Tenover FC (1998) GyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 42: 2661-7.
28. Lindgren PK, Karlsson A, Hughes D (2003) Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 47: 3222-32.
29. Jacoby GA, Chow N, Waites KB (2003) Prevalence of plasmid-mediated quinolone resistance. Antimicrob Agents Chemother 47: 559-62.
30. Brenwald NP, Gill MJ, Wise R (1997) The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin. J Antimicrob Chemother 40: 458-60.
31. Barrett TJ, Lior H, Green J, et al. (1994) Laboratory investigation of a multistate food-borne outbreak of Escherichia coli O157:H7 by using pulsed-field gel electrophoresis and phage typing. J Clin Microbiol 32: 3013-17.
32. Liesgang A, Tschape H (2002) Modified pulsed-field gel electrophoresis method for DNA degradation-sensitive Salmonella enterica and Escherichia coli strains. Int J Med Microbiol 291: 645-8.
33. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, et al. (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33: 2233-9.
34. Clinical and Laboratory Standards Institute (2005) Performance standards for antimicrobial susceptibility testing 15th informational supplement. Approved standard M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
35. Hao C, Lissemore L, Nguyen B, Kleywegt S, Yang P, et al. (2006) Determination of pharmaceuticals in environmental waters by liquid chromatography/electrospray ionization/tandem mass spectrometry. Anal Bioanal Chem 384: 505-13.
36. Popelka P, Nagy J, Popelka P, Sokol J, Hajurka J, et al. (2003) Comparison of various methods for penicillin residue detection in cow milk after intramammary and parenteral treatment. Bull. Vet. Inst Pulawy 47: 203-209.